Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation

Genes and Development

Volumn 17, Issue 16, 2003, Pages 1979-1991

  Kim, Sunhwa ^a   Koga, Takako ^a,b   Isobe, Miho ^a,b   Kern, Britt E ^c   Yokochi, Taeko ^a   Chin, Y Eugene ^d   Karsenty, Gerard ^c   Taniguchi, Tadatsugu ^a   Takayanagi, Hiroshi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Bone remodeling; Osteoblast; Runx2; Stat1

Indexed keywords

BETA INTERFERON; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX2; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MASS; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE FUNCTION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SKELETON; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

NON-PROGRAMMATIC;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CELL DIFFERENTIATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CYTOPLASM; DNA-BINDING PROTEINS; INTERFERON-STIMULATED GENE FACTOR 3; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASM PROTEINS; OSTEOBLASTS; RETROVIRIDAE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MAMMALIA;

EID: 0042662937     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1119303     Document Type: Article

References (46)

1. Bellido, T., Borba, V.Z., Roberson, P., and Manolagas, S.C. 1997. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138: 3666-3676.
2. Chatterjee-Kishore, M., Wright, K.L., Ting, J.P., and Stark, G.R. 2000. How Stat1 mediates constitutive gene expression: A complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J. 19: 4111-4122.
3. Daluiski, A., Engstrand, T., Bahamonde, M.E., Gamer, L.W., Agius, E., Stevenson, S.L., Cox, K., Rosen, V., and Lyons, K.M. 2001. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat. Genet. 27: 84-88.
4. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. 1996. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84: 911-921.
5. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L., and Karsenty, G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
6. Ducy, P., Schinke, T., and Karsenty, G. 2000. The osteoblast: A sophisticated fibroblast under central surveillance. Science 289: 1501-1504.
7. Heldin, C.H., Miyazono, K., and ten Dijke, P. 1997. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471.
8. Ito, Y. and Miyazono, K. 2003. RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr. Opin. Genet. Dev. 13: 43-47.
9. Javed, A., Gutierrez, S., Montecino, M., van Wijnen, A.J., Stein, J.L., Stein, G.S., and Lian, J.B. 1999. Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. Mol. Cell. Biol. 19: 7491-7500.
10. Jochum, W., David, J.P., Elliott, C., Wutz, A., Plenk Jr., H., Matsuo, K., and Wagner, E.F. 2000. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6: 980-984.
11. Kagoshima, H., Akamatsu, Y., Ito, Y., and Shigesada, K. 1996. Functional dissection of the α and β subunits of transcription factor PEBP2 and the redox susceptibility of its DNA binding activity. J. Biol. Chem. 271: 33074-33082.
12. Karsenty, G. and Wagner, E.F. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2: 389-406.
13. Kimura, T., Kadokawa, Y., Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Tarutani, M., Tan, R.S., Takasugi, T., Matsuyama, T., et al. 1996. Essential and non-redundant roles of p48 (ISGF3 γ) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1: 115-124.
14. Komori, T. 2002. Runx2, a multifunctional transcription factor in skeletal development. J. Cell Biochem. 87: 1-8.
15. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
16. Kong, Y.Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309.
17. Lee, K.S., Kim, H.J., Li, Q.L., Chi, X.Z., Ueta, C., Komori, T., Wozney, J.M., Kim, E.G., Choi, J.Y., Ryoo, H.M., et al. 2000. Runx2 is a common target of transforming growth factor β1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol. Cell. Biol. 20: 8783-8792.
18. Liu, W., Toyosawa, S., Furuichi, T., Kanatani, N., Yoshida, C., Liu, Y., Himeno, M., Narai, S., Yamaguchi, A., and Komori, T. 2001. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155: 157-166.
19. Manolagas, S.C. 2000. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21: 115-137.
20. Massague, J. 2000. How cells read TGF-β signals. Nat. Rev. Mol. Cell. Biol. 1: 169-178.
21. Meraz, M.A., White, J.M., Sheehan, K.C., Bach, E.A., Rodig, S.J., Dighe, A.S., Kaplan, D.H., Riley, J.K., Greenlund, A.C., Campbell, D., et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
22. Ogata, N., Chikazu, D., Kubota, N., Terauchi, Y., Tobe, K., Azuma, Y., Ohta, T., Kadowaki, T., Nakamura, K., and Kawaguchi, H. 2000. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105: 935-943.
23. Olsen, B.R., Reginato, A.M., and Wang, W. 2000. Bone development. Annu. Rev. Cell., Dev. Biol. 16: 191-220.
24. O'Shea, J.J., Gadina, M., and Schreiber, R.D. 2002. Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 109 Suppl: S121-S131.
25. Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen, B.R., et al. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89: 765-771.
26. Rodan, G.A. and Martin, T.J. 2000. Therapeutic approaches to bone diseases. Science 289: 1508-1514.
27. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.M., Maroteaux, P., Le Merrer, M., and Munnich, A. 1994. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371: 252-254.
28. Sabatakos, G., Sims, N.A., Chen, J., Aoki, K., Kelz, M.B., Amling, M., Bouali, Y., Mukhopadhyay, K., Ford, K., Nestler, E.J., et al. 2000. Overexpression of ΔFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med. 6: 985-990.
29. Sahni, M., Ambrosetti, D.C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. 1999. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes & Dev. 13: 1361-1366.
30. Sahni, M., Raz, R., Coffin, J.D., Levy, D., and Basilico, C. 2001. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128: 2119-2129.
31. Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., and Schreiber, R.D. 1998. How cells respond to interferons. Annu. Rev. Biochem. 67: 227-264.
32. Su, W.C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W.A., and Fu, X.Y. 1997. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386: 288-292.
33. Takayanagi, H., Iizuka, H., Juji, T., Nakagawa, T., Yamamoto, A., Miyazaki, T., Koshihara, Y., Oda, H., Nakamura, K., and Tanaka, S. 2000a. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43: 259-269.
34. Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., et al. 2000b. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408: 600-605.
35. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., et al. 2002a. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3: 889-901.
36. Takayanagi, H., Kim, S., Matsuo, K., Suzuki, H., Suzuki, T., Sato, K., Yokochi, T., Oda, H., Nakamura, K., Ida, N., et al. 2002b. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416: 744-749.
37. Takayanagi, H., Kim, S., and Taniguchi, T. 2002c. Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-S232.
38. Taniguchi, T., Ogasawara, K., Takaoka, A., and Tanaka, N. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19: 623-655.
39. Tanizawa, T., Yamaguchi, A., Uchiyama, Y., Miyaura, C., Ikeda, T., Ejiri, S., Nagal, Y., Yamato, H., Murayama, H., Sato, M., et al. 2000. Reduction in bone formation and elevated bone resorption in ovariectomized rats with special reference to acute inflammation. Bone 26: 43-53.
40. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
41. Thirunavukkarasu, K., Mahajan, M., McLarren, K.W., Stifani, S., and Karsenty, G. 1998. Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfβ. Mol. Cell. Biol. 18: 4197-4208.
42. Wang, E.A., Rosen, V., D'Alessandro, J.S., Bauduy, M., Cordes, P., Harada, T., Israel, D.I., Hewick, R.M., Kerns, K.M., LaPan, P., et al. 1990. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. 87: 2220-2224.
43. Wu, T.R., Hong, Y.K., Wang, X.D., Ling, M.Y., Dragoi, A.M., Chung, A.S., Campbell, A.G., Han, Z.Y., Feng, G.S., and Chin, Y.E. 2002. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 277: 47572-47580.
44. Yamaguchi, A., Katagiri, T., Ikeda, T., Wozney, J.M., Rosen, V., Wang, E.A., Kahn, A.J., Suda, T., and Yoshiki, S. 1991. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J. Cell Biol. 113: 681-687.
45. Yoshida, Y., Tanaka, S., Umemori, H., Minowa, O., Usui, M., Ikematsu, N., Hosoda, E., Imamura, T., Kuno, J., Yamashita, T., et al. 2000. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103: 1085-1097.
46. Zhang, Y.W., Yasui, N., Ito, K., Huang, G., Fujii, M., Hanai, J., Nogami, H., Ochi, T., Miyazono, K., and Ito, Y. 2000. A RUNX2/PEBP2α/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc. Natl. Acad. Sci. 97: 10549-10554.